Melittin is a Chinese traditional medicine for treating chronic inflammation, immunological diseases and cancers, however, the efficacy of melittin and its mechanism for treating pancreatic ductal adenocarcinoma (PDAC) are still unknown. Here we investigated the anti-cancer activity of melittin and its regulated mechanism(s) in the PDAC models. Melittin was found to suppress tumor growth by promoting cell apoptosis and cell-cycle arrest. Interestingly, the microarray analyses demonstrated that melittin significantly regulated cholesterol biosynthesis pathway during treatment.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2pvaARC
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Purpose To test the effects of 4 weeks of unilateral low-load resistance training (LLRT), with and without blood flow restricti...
-
Relativistic hydrodynamics has been quite successful in explaining the collective behaviour of the QCD matter produced in high energy heavy-...
-
36 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: quality...
-
by Claudia Zielke, Ondrej Kosik, Marie-Louise Ainalem, Alison Lovegrove, Anna Stradner, Lars Nilsson An extraction method for mixed-linkage...
-
The genital mucosa is a barrier that is constantly exposed to a variety of pathogens, allergens, and external stimuli. Although both allerge...
-
by Mark A. Valasek, Irene Thung, Esha Gollapalle, Alexey A. Hodkoff, Kaitlyn J. Kelly, Joel M. Baumgartner, Vera Vavinskaya, Grace Y. Lin, A...
-
The receptor tyrosine kinase KIT is an established oncogenic driver of tumor growth in certain tumor types, including gastrointestinal strom...
-
The main idea behind this work was demonstrated in a form of a new thermoelectrochromic sensor on a flexible substrate using graphene as an ...
-
Abstract There are limited published data on the burden of rare cancers in the United States. By using data from the North American Associ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου